Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Denali Therapeutics Inc. on May 30, 2019. The company is an emerging growth company incorporated in Delaware, with its common stock (DNLI) trading on the NASDAQ Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (April 11, 2019), 95,437,937 shares were outstanding. 84,045,696 shares (88.06%) were represented at the meeting. The following matters were approved:
- Election of Directors: Three Class II directors were elected to serve until the 2022 annual meeting: Peter Klein, Robert Nelsen, and Vicki Sato, Ph.D.
- Ratification of Auditors: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific vote counts for each director nominee to assess shareholder support levels.
- Confirm the tenure of the newly elected Class II directors (until 2022).
- Note the high attendance rate (88.06%) indicating significant shareholder engagement.
- Review subsequent filings for the company's financial performance, as this 8-K contains no financial data.